Management to participate in investor meetings on July 14-15 in Boston Denver, CO, July 10, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation oral PDE4 inhibitor prodrugs for inflammatory bowel disease, today announced that JD Finley, Chief Executive Officer, and Dr. Mitchell Jones, President & Chief Medical Officer, will participate in the Leerink Partners Therapeutics Forum, taking place July 14-1 ...

分析师背景与研究方法 - 分析师Max专注于生物技术、医疗保健和科技行业的独立股票研究 [1] - 其投资方法基于基本面分析，结合详细的财务建模、估值分析以及对临床试验数据、监管路径、竞争动态、商业化潜力和长期业务基本面的深入研究 [1] - 分析师通过在德意志联邦银行和安永的工作经历，加深了对金融系统和专业分析标准的理解 [1] - 其目标是通过独立、研究驱动的分析，将临床和财务数据转化为可行的投资见解 [1]